Published in Cardiovascular Device Liability Week, January 2nd, 2005
According to recent research published in the European Journal of Human Genetics, "the rate-limiting enzyme in the conversion of cholesterol into bile acids is cholesterol 7alpha-hydroxylase (CYP7A1). An A to C substitution 278 bp upstream in the promoter of the CYP7A1 gene was found to be associated with variations in serum lipid levels in normolipidemic populations."
"In the present study, we investigated the involvement of this polymorphism in four different lipid disorders: hypertriglyceridamia (HTG), combined hyperlipidemia (CH), familial dysbetalipoproteinemia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.